December 8, 2025BloodOpen Access

Evaluation of response assessment in chronic lymphocytic leukaemia using measurable residual disease by flow cytometry: Prospective observational study.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Prospective observational study shows measurable residual disease impacts treatment efficacy in chronic lymphocytic leukaemia.

In the cohort, complete responses were significantly higher in chemoimmunotherapy compared to targeted therapy, indicating efficacy variations.
The analysis highlighted measurable residual disease's role in predicting long-term outcomes with a notable focus on treatment efficacy in chronic lymphocytic leukaemia.
Assessment compared iwCLL 2018 response criteria and measurable residual disease with notable findings in targeted therapy outcomes.
Results indicated that treatment efficacy differs across response criteria, emphasizing the need for further studies on chronic lymphocytic leukaemia management.

Adhikari et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark